1. Medtech Insight
  2. >>Business
  3. >>Financing

Cardinal Agrees To Sell Cordis For $1Bn To Hellman & Friedman

 
• By Marion Webb

Cardinal said it remains “committed to its medical distribution and global medical products businesses” despite the divesture of Cordis.

Divesting

Cardinal Health announced on 12 March it agreed to sell Cordis Corp., its minimally invasive cardiovascular technology business, to private equity firm Hellman & Friedman for about $1bn.

The deal is expected to close in the first half of Cardinal Health’s fiscal year 2022, subject to customary closing...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Financing

More from Business

Medicare Tricuspid Regurgitation Coverage Decision Big Win For Abbott

 
• By Brian Bossetta

Medicare beneficiaries with tricuspid regurgitation will now have access to an innovative treatment from Abbott that offers a minimally invasive alternative to open-heart surgery.

Waters’ Purchase Of BD Biosciences & Dx Brings Growth Potential Alongside Trade-Offs

 
• By Marion Webb

Waters Corp. will acquire Becton Dickinson’s Biosciences and Diagnostics business for $17.5bn, doubling its TAM to $40B. Analysts praise the flow cytometry addition but see weaker growth in diagnostics.

Medtronic, Philips Cement New Pact To Embed Next-Gen Tech In Monitoring Platforms

 
• By Shubham Singh

Under the terms of the new agreement, Philips will also begin bundling essential supplies – including ECG, noninvasive blood pressure (NIBP) components, and batteries – with its Medtronic-enabled monitors.